Saturday 17 October 2026
Export SILO’s income statement to Excel — free account
Silo Pharma, Inc.
SILO Healthcare Biotechnology
Silo Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $72,100.00, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 73.3% and free cash flow grew 39.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.18
0.02
−1.67%
Follow SILO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | 68.58 | 39.60 | 89.47 | |
P/FCF ratio |
— | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
— | (6.00) | (3.65) | (6.74) | |
P/B ratio |
— | 0.87 | 0.45 | 1.29 | |
Price to Tangible BV |
— | 0.90 | 0.47 | 1.35 | |
EV/Sales |
— | (15.15) | (55.61) | 8.04 | |
EV/EBITDA |
— | 0.23 | 0.94 | 0.00 | |
EV/Operating CF |
— | 0.28 | 0.86 | (0.12) | |
EV/FCF |
— | 0.29 | 0.86 | (0.12) | |
Quick Ratio |
4.90 | 8.56 | 10.55 | 8.28 | |
Current Ratio |
5.36 | 9.65 | 11.36 | 8.70 | |
Net Debt/EBITDA |
6.05 | 3.85 | 8.75 | 5.11 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.01 | 0.01 | 0.01 | |
Operating CF/Net income |
0.94 | 0.50 | 0.89 | 0.86 | |
Capex/Depreciation |
0.00 | (0.16) | (172.38) | (25.86) | |
Interest Coverage |
(320.31) | (469.03) | (24.05) | (1,279.44) | |
Research and Development Expense of Revenue |
0.00% | 5,629.44% | 1,700.00% | 3,020.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 3,215.00% | 2,655.00% | 3,362.22% | |
Intangible Assets out of Total Assets |
0.04 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
0.00% | 4,281.11% | 290.56% | 3,141.67% | |
Graham Net Nets |
— | 1.11 | 2.14 | 0.74 | |
Graham Number |
— | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
— | (119.39%) | (158.75%) | (137.61%) | |
Free Cash Flow Yield |
— | (76.93%) | (163.47%) | (74.49%) | |
Revenue per Share |
0.00 | 0.02 | 0.03 | 0.03 | |
Operating CF per Share |
(0.71) | (0.90) | (1.40) | (1.54) | |
Capex per Share |
0.00 | (0.01) | (0.89) | (0.12) | |
Free Cash Flow per Share |
(0.71) | (0.90) | (2.29) | (1.66) | |
Cash per Share |
4.76 | 6.60 | 12.27 | 9.43 | |
Shareholders Equity per Share |
4.45 | 6.21 | 11.28 | 8.05 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.45 | 6.21 | 11.28 | 8.05 | |
Free Cash Flow |
(0.78) | (0.83) | (1.28) | (1.03) | |
Working Capital |
4.65 | 6.10 | 6.74 | 5.46 | |
Capital Expenditures |
0.00 | 0.00 | (0.50) | (0.07) | |
Net Current Asset Value |
4.65 | 5.47 | 6.09 | 4.79 | |
EV/EBIT |
— | 0.23 | 0.94 | 0.00 | |
Capex to Sales |
0.00 | 0.27 | 27.77 | 4.17 | |
Price to Operating Income |
— | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.67 | 0.87 | 1.08 | 0.80 | |
Average Assets |
6.30 | 6.46 | 7.51 | 7.48 | |
Average Common Equity |
4.90 | 4.85 | 5.67 | 5.90 |
Columns are period end dates